Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44364   clinical trials with a EudraCT protocol, of which   7388   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
    Select Country:
    		 Select Age Range:
    Select Trial Status:
    		 Select Trial Phase:
    Select Gender:
    Select Date Range:
    to
    Select Rare Disease:
    IMP with orphan designation in the indication
    Orphan Designation Number:
    Results Status:
    Clear advanced search filters
     
    634 result(s) found. Displaying page 1 of 32.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2010-019252-41 Sponsor Protocol Number: 242187 Start Date*: 2011-08-03
    Sponsor Name:VU University Medical Center
    Full Title: DALI dosing study of Vitamin D in obese pregnant women
    Medical condition: Gestational diabetes
    Disease: Version SOC Term Classification Code Term Level
    14.0 10027433 - Metabolism and nutrition disorders 10012606 Diabetes mellitus gestational LLT
    Population Age: Adults Gender: Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-003549-16 Sponsor Protocol Number: Tulir 03/01 Start Date*: 2006-03-08
    Sponsor Name:NeuroBiotec GmbH
    Full Title: Transdermal Lisuride: A double-blind, randomized, active- and placebo-controlled multi-centre phase III efficacy trial for the treatment of patients with Restless Legs Syndrome (RLS)
    Medical condition: Idiopathic and Uremic Restless Legs Syndrome (RLS)
    Disease: Version SOC Term Classification Code Term Level
    7.0 10058920 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-000648-15 Sponsor Protocol Number: BH4/III/05/001 Start Date*: 2006-06-08
    Sponsor Name:ORPHANETICS Pharma Entwicklungs- GmbH
    Full Title: A double-blind, placebo-controlled, multicentre study with an open-label extension to evaluate the efficacy and safety of tetrahydrobiopterin (BH4) in children and adolescents with hyperphenylalani...
    Medical condition: Hyperphenylalaninemia due to phenylalanine hydroxylase deficiency. Phenotypes: classic phenylketonuria (PKU), mild PKU (MPK) or mild hyperphenylalaninemia (HPA).
    Disease: Version SOC Term Classification Code Term Level
    81 10034873 LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-023923-78 Sponsor Protocol Number: FH-1.3 Start Date*: 2011-03-30
    Sponsor Name:Forsight Vision 4, Inc.
    Full Title: “ A prospective clinical trial to evaluate the V4 Drug delivery device for long term delivery of Ranibizumab for the Treatment of Choroidal Neovascularization”
    Medical condition: Choroidal Neovascularization (CNV) secondary to Age-related Macular Degeneration (AMD) is among the leading causes of blindness in the world. The primary treatment modality is injection of Lucentis...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-001589-42 Sponsor Protocol Number: Tulir 02/01 Start Date*: 2004-12-25
    Sponsor Name:NeuroBiotec GmbH
    Full Title: Transdermal lisuride: Phase II/III study (efficacy and tolerance) of transdermal lisuride (patches) in patients with Restless Legs Syndrome (RLS)
    Medical condition: Patients suffering from Restless Legs Syndrome (RLS)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-003858-29 Sponsor Protocol Number: CISCA-Studie“ Protokollversion 4.0 Start Date*: 2008-02-27
    Sponsor Name:Universitätsklinikum Tübingen, Medizinische Klinik I
    Full Title: Prospektive multizentrische Phase-III-Studie zur ambulanten Therapie mit Capecitabin versus Cisplatin plus Capecitabin beim fortgeschrittenen Adenokarzinom der Gallenblase und Gallenwege („CISCA-St...
    Medical condition: Karzinome der Gallenblase, Karzinome der extrahepatischen Gallengänge
    Disease:
    Population Age: Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-004961-26 Sponsor Protocol Number: 12-009 Start Date*: 2015-12-15
    Sponsor Name:McMaster University
    Full Title: Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY): A Multi-Center Randomized Controlled Study Comparing Alternative Antibiotic Regimens in Patients Undergoing Tumor Resections with Endopro...
    Medical condition: ? Patients with a primary bone malignancy or soft-tissue sarcoma that has invaded a lower extremity bone that are undergoing surgical treatment to resect the tumor and functionally reconstruct the ...
    Disease: Version SOC Term Classification Code Term Level
    18.1 10042613 - Surgical and medical procedures 10064736 Antibiotic prophylaxis PT
    18.1 100000004862 10056641 Post procedural site wound infection LLT
    18.1 10042613 - Surgical and medical procedures 10068943 Limb reconstructive surgery PT
    18.1 10042613 - Surgical and medical procedures 10036894 Prophylactic antibiotic therapy LLT
    18.1 10042613 - Surgical and medical procedures 10005978 Bone lesion excision PT
    18.1 10042613 - Surgical and medical procedures 10073235 Bone prosthesis insertion PT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006007 Bone sarcoma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-000860-28 Sponsor Protocol Number: 02CLLIII Start Date*: 2004-12-02
    Sponsor Name:ribosepharm GmbH
    Full Title: PHASE III, OPEN-LABEL, RANDOMIZED, MULTICENTER EFFICACY AND SAFETY STUDY OF BENDAMUSTINE HYDROCHLORIDE VERSUS CHLORAMBUCIL IN TREATMENT-NAÏVE PATIENTS WITH (BINET STAGE B/C) B-CLL REQUIRING THERAPY
    Medical condition: Hematopoietic insufficiency with non-hemolysis-induced Hb <10 g/dL Thrombocytopenia <100x109/L (equivalent to Binet stage C) B symptoms Rapidly progressive disease (such as rapid lymphoma growth, r...
    Disease: Version SOC Term Classification Code Term Level
    7 10008956 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-003399-30 Sponsor Protocol Number: I8B-MC-ITSG Start Date*: 2018-10-24
    Sponsor Name:Eli Lilly and Company
    Full Title: A Prospective, Randomized, Double-Blind Comparison of LY900014 and Fiasp®, Both in Combination with Basal Insulin in Adults with Type 1 Diabetes, PRONTO-Compare
    Medical condition: Diabetes Mellitus, Type 1
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10067584 Type 1 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-002264-27 Sponsor Protocol Number: ENGOT-ov54/Swiss-GO-2/MATAO Start Date*: 2021-03-17
    Sponsor Name:Swiss GO Trial Group
    Full Title: MAintenance Therapy with Aromatase inhibitor in epithelial Ovarian cancer: a randomized double-blinded placebo-controlled multi-center phase III Trial (ENGOT-ov54/Swiss-GO-2/MATAO) including LOGOS ...
    Medical condition: Patients with low and high grade serous and endometrioid ovarian cancer patients.
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Trial now transitioned) DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-002460-13 Sponsor Protocol Number: VITDALIZE Start Date*: 2017-01-03
    Sponsor Name:Medical University of Graz
    Full Title: Effect of high-dose vitamin D3 on 28-day mortality in adult critically ill patients with severe vitamin D deficiency: a multicenter, placebo-controlled double-blind phase III RCT
    Medical condition: Adult critically ill patients with severe vitamin D deficiency
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Trial now transitioned) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2017-002163-17 Sponsor Protocol Number: 15-138 Start Date*: 2018-10-25
    Sponsor Name:RWTH Aachen University represented by the Center for Translational & Clinical Research Aachen (CTC-A)
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTRE STUDY OF THE EFFICACY AND SAFETY OF NICOTINAMIDE IN PATIENTS WITH FRIEDREICHS ATAXIA.
    Medical condition: Friedreich Ataxia
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) AT (Prematurely Ended) GB (GB - no longer in EU/EEA) ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2017-000381-29 Sponsor Protocol Number: SCY-078-301 Start Date*: 2017-07-17
    Sponsor Name:SCYNEXIS, Inc.
    Full Title: Open-Label Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients with Fungal Diseases that are Refractory to, Resistant to or Intolerant of Standard Antifungal Treatment (FURI)
    Medical condition: Patients > 18 years of age with a documented invasive and/or severe fungal disease that has been intolerant, resistant or refractory (rIFI) to Standard of Care (SoC) antifungal treatment.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) ES (Ongoing) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2020-000605-84 Sponsor Protocol Number: XPORT-DLBCL-030 Start Date*: 2020-09-16
    Sponsor Name:Karyopharm Therapeutics Inc.
    Full Title: A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR DL...
    Medical condition: Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR DLBCL)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10012856 Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation) recurrent LLT
    21.1 100000004864 10012857 Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation) refractory LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing) FR (Ongoing) IT (Trial now transitioned) GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-005106-23 Sponsor Protocol Number: ALLSCT06BFMi Start Date*: 2007-06-27
    Sponsor Name:St. Anna Kinderkrebsforschung
    Full Title: Allogenic stem cell transplantation in children and adolescents with acute lymphoblastic leukaemia
    Medical condition: very high risk acute lymphoblastic leukaemia in children and adolescents with indicaton for allogenic hematopoetic stem cell transplantation
    Disease: Version SOC Term Classification Code Term Level
    8.1 10000844 Acute lymphoblastic leukaemia LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) IT (Ongoing)
    Trial results: View results
    EudraCT Number: 2010-019497-32 Sponsor Protocol Number: PGL09-027 Start Date*: 2010-11-09
    Sponsor Name:PregLem S.A.
    Full Title: A Phase III, multicentre, clinical study investigating the efficacy and safety of three successive periods of 3-month open-label PGL4001 treatment, each followed by ten days of double-blind treatme...
    Medical condition: Uterine myomas are benign, monoclonal, hormone-sensitive, smooth muscle tumours of the uterus. They are the most common tumour of the female reproductive tract in pre-menopausal women and mostly as...
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10046801 Uterine myoma LLT
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed) PL (Completed) AT (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-001465-33 Sponsor Protocol Number: PGL11-024 Start Date*: 2012-07-09
    Sponsor Name:PregLem S.A.
    Full Title: A Phase III, multicentre, extension study investigating the efficacy and safety of repeated intermittent 3-month courses of open-label administration of ulipristal acetate, in subjects with symp...
    Medical condition: Uterine myomas are benign, monoclonal, hormone-sensitive, smooth muscle tumours of the uterus. They are the most common tumour of the female reproductive tract in pre-menopausal women and mostly a...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10046801 Uterine myoma LLT
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed) AT (Completed) ES (Ongoing) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-003078-15 Sponsor Protocol Number: D5180C00007 Start Date*: 2018-07-04
    Sponsor Name:AstraZeneca AB
    Full Title: A Multicentre, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults and Adolescents with Severe Uncontrolled Asth...
    Medical condition: Severe uncontrolled Asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) FR (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2008-007295-14 Sponsor Protocol Number: 26081-22086 Start Date*: 2010-11-17
    Sponsor Name:European Organization for Research and Treatment of Cancer (EORTC)
    Full Title: Phase III intergroup Study of Radiotherapy versus Temozolomide Alone versus Radiotherapy with concomitant and adjuvant Temozolomide for Patients with 1p/19q Codeleted Anaplastic Glioma.
    Medical condition: Newly Diagnosed Anaplastic Glioma with Chromosomal co-deletions of 1p and 19q
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10002224 Anaplastic astrocytoma PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027744 Mixed astrocytoma-oligodendroglioma LLT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065443 Malignant glioma PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026659 Malignant oligodendroglioma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) BE (Prematurely Ended) GB (GB - no longer in EU/EEA) AT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-005639-65 Sponsor Protocol Number: GEICAM/2017-01_IBCSG62-20_BIG18-04 Start Date*: 2021-05-25
    Sponsor Name:GEICAM (Fundación Grupo Español de Investigación en Cáncer de Mama)
    Full Title: A randomized phase III trial of trastuzumab + ALpelisib +/- fulvestrant versus trastuzumab + chemotherapy in patients with PIK3CA mutated previously treated HER2+ Advanced BrEasT cancer. “ALPHABET ...
    Medical condition: PIK3CA mutated HER2+ advanced or relapsed breast cancer (BC) previously treated with trastuzumab and trastuzumab emtansine (T-DM1)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER2 positive breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) AT (Completed) FR (Prematurely Ended) NL (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Nov 08 20:06:54 CET 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA